Allergy Therapeutics (LON:AGY) Shares Down 11.3% – Time to Sell?

Allergy Therapeutics plc (LON:AGY) shares dropped 11.3% on Wednesday . The company traded as low as GBX 6.18 and last traded at GBX 6.30. 225,345 shares traded hands during trading, a decline of 17% from the average daily volume of 271,766 shares. The stock had previously closed at GBX 7.10.

Allergy Therapeutics Trading Up 4.2%

The stock has a market capitalization of £426.37 million, a P/E ratio of -6.94, a PEG ratio of -30.70 and a beta of 0.85. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The business’s 50 day simple moving average is GBX 8.89 and its 200-day simple moving average is GBX 10.28.

Allergy Therapeutics (LON:AGY) last issued its earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The business had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. As a group, analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.